NASDAQ:VXRT Vaxart (VXRT) Stock Price, News & Analysis → Are you prepared for a Chinese 'invasion?' (From Behind the Markets) (Ad) Free VXRT Stock Alerts $0.53 -0.05 (-8.69%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$0.52▼$0.6350-Day Range$0.57▼$1.0852-Week Range$0.52▼$1.54Volume25.26 million shsAverage Volume2.61 million shsMarket Capitalization$92.88 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vaxart alerts: Email Address Vaxart MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside471.2% Upside$3.00 Price TargetShort InterestBearish10.69% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.49) to ($0.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.79 out of 5 starsMedical Sector829th out of 913 stocksBiological Products, Except Diagnostic Industry143rd out of 152 stocks 3.5 Analyst's Opinion Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxart has received no research coverage in the past 90 days.Read more about Vaxart's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.69% of the outstanding shares of Vaxart have been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.Change versus previous monthShort interest in Vaxart has recently increased by 1.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VXRT. Previous Next 2.6 News and Social Media Coverage News SentimentVaxart has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Vaxart this week, compared to 1 article on an average week.Search Interest17 people have searched for VXRT on MarketBeat in the last 30 days. This is an increase of 240% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Vaxart is held by insiders.Percentage Held by InstitutionsOnly 18.05% of the stock of Vaxart is held by institutions.Read more about Vaxart's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vaxart are expected to grow in the coming year, from ($0.49) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vaxart's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)Click Here To Read More About This Game Changing AI Tool About Vaxart Stock (NASDAQ:VXRT)Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.Read More VXRT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VXRT Stock News HeadlinesJune 17 at 4:05 PM | globenewswire.comVaxart Provides Business UpdateJune 13, 2024 | globenewswire.comVaxart Announces $40 Million Underwritten Offering of Common StockJune 13, 2024 | globenewswire.comVaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateJune 11, 2024 | americanbankingnews.comVaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving Average of $0.91May 23, 2024 | globenewswire.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 14, 2024 | insidermonkey.comVaxart, Inc. (NASDAQ:VXRT) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comVaxart Inc (VXRT) Q1 2024 Earnings Call Transcript Highlights: Promising Developments and ...May 13, 2024 | globenewswire.comVaxart Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 12, 2024 | markets.businessinsider.comVaxart earnings preview: what to expectMay 7, 2024 | finance.yahoo.comVaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13April 30, 2024 | globenewswire.comVaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating MothersApril 9, 2024 | investorplace.comElection Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?March 27, 2024 | globenewswire.comVaxart to Present at World Vaccine Congress Washington 2024 on April 3March 20, 2024 | globenewswire.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 17, 2024 | finance.yahoo.comEstimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)March 15, 2024 | finance.yahoo.comVaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | investorplace.comVXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023March 14, 2024 | finance.yahoo.comVaxart Inc (VXRT) Reports Full Year 2023 Financial ResultsMarch 14, 2024 | globenewswire.comVaxart Provides Business Update and Reports Full Year 2023 Financial ResultsMarch 7, 2024 | globenewswire.comVaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14March 6, 2024 | marketwatch.comVaxart Names Steven Lo President, Chief ExecutiveMarch 6, 2024 | globenewswire.comVaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and DirectorFebruary 20, 2024 | finance.yahoo.comVAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?February 5, 2024 | finance.yahoo.comVaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 ChallengeJanuary 16, 2024 | marketwatch.comVaxart CEO Resigns; Biotech Raises $10 Million in Stock SaleSee More Headlines Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/17/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CUSIPN/A CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees109Year Founded2004Price Target and Rating Average Stock Price Target$3.00 High Stock Price Target$4.00 Low Stock Price Target$2.00 Potential Upside/Downside+471.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,460,000.00 Net Margins-920.00% Pretax Margin-916.88% Return on Equity-121.06% Return on Assets-79.98% Debt Debt-to-Equity RatioN/A Current Ratio3.14 Quick Ratio3.14 Sales & Book Value Annual Sales$9.28 million Price / Sales10.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book1.38Miscellaneous Outstanding Shares176,838,000Free Float171,533,000Market Cap$92.88 million OptionableOptionable Beta0.65 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Steven Lo (Age 57)President, CEO & Director Mr. Phillip Eric Lee (Age 36)CFO, Principal Financial Officer & Principal Accounting Officer Dr. Raymond D. Stapleton Jr. (Age 53)Ph.D., Chief Technology Officer Ms. Shaily Jaini GargSenior Vice President of Clinical Development & Project ManagementDr. Rajesh Kapoor Ph.D.Senior Vice President of QualityKey CompetitorsAthira PharmaNASDAQ:ATHAAligos TherapeuticsNASDAQ:ALGSInovio PharmaceuticalsNASDAQ:INOCabaletta BioNASDAQ:CABAAdaptive BiotechnologiesNASDAQ:ADPTView All CompetitorsInstitutional OwnershipRA Capital Management L.P.Bought 15,384,615 shares on 5/17/2024Ownership: 8.700%Tidal Investments LLCBought 43,449 shares on 5/17/2024Ownership: 0.025%Vanguard Group Inc.Bought 1,404,391 shares on 5/10/2024Ownership: 4.778%PFG Investments LLCBought 29,450 shares on 4/22/2024Ownership: 0.017%Kingswood Wealth Advisors LLCBought 25,000 shares on 4/15/2024Ownership: 0.014%View All Institutional Transactions VXRT Stock Analysis - Frequently Asked Questions Should I buy or sell Vaxart stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VXRT shares. View VXRT analyst ratings or view top-rated stocks. What is Vaxart's stock price target for 2024? 2 equities research analysts have issued 12 month price objectives for Vaxart's shares. Their VXRT share price targets range from $2.00 to $4.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 471.2% from the stock's current price. View analysts price targets for VXRT or view top-rated stocks among Wall Street analysts. How have VXRT shares performed in 2024? Vaxart's stock was trading at $0.5728 on January 1st, 2024. Since then, VXRT stock has decreased by 8.3% and is now trading at $0.5252. View the best growth stocks for 2024 here. When is Vaxart's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our VXRT earnings forecast. How were Vaxart's earnings last quarter? Vaxart, Inc. (NASDAQ:VXRT) released its quarterly earnings data on Monday, May, 13th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02. The biotechnology company had revenue of $2.18 million for the quarter. Vaxart had a negative net margin of 920.00% and a negative trailing twelve-month return on equity of 121.06%. What ETF holds Vaxart's stock? Amplify Treatments, Testing and Advancements ETF holds 36,209 shares of VXRT stock, representing 0.29% of its portfolio. When did Vaxart's stock split? Shares of Vaxart reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), Organigram (OGI) and Novan (NOVN). Who are Vaxart's major shareholders? Vaxart's stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (8.70%), Vanguard Group Inc. (4.78%), Tidal Investments LLC (0.02%), PFG Investments LLC (0.02%) and Kingswood Wealth Advisors LLC (0.01%). Insiders that own company stock include Fuad Ahmad, Margaret Echerd, Robert A Yedid, Sean Tucker and W Mark Watson. View institutional ownership trends. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VXRT) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.